Search - tctmd.com

Displaying 161 - 180 of 294

Sort: Relevancy | Date

Presentation TCT 2018

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Presenter: David J. Cohen, Sunil V. Rao, David J. Maron

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

Ultra-Thin Strut DES: A Meaningful Advance?

Presenter: Renu Virmani, Clemens von Birgelen, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Presenter: Renu Virmani, Clemens von Birgelen, David E. Kandzari

September 22, 2018

Presentation TCT 2018

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Presenter: Renu Virmani, Clemens von Birgelen, Michael Joner

September 22, 2018

News Conference News EuroPCR 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

Caitlin E. Cox

May 30, 2018

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

Caitlin E. Cox

May 25, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News ISET 2018

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

Caitlin E. Cox

February 08, 2018

News Industry News

SELUTION™ First-in-Man Study Achieves Primary Endpoint

January 31, 2018

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

News Opinion Off Script TCT 2017

Off Script: Focusing on the Future

Kwan S. Lee

October 31, 2017

Presentation TCT 2017

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Presenter: Robert A. Byrne, Ran Kornowski, Juan F. Granada

October 30, 2017

$Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy$

Presentation TCT 2017

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

Presenter: Robert A. Byrne, Ran Kornowski, Ron Waksman

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Advertisement

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Ultra-Thin Strut DES: A Meaningful Advance?

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

SELUTION™ First-in-Man Study Achieves Primary Endpoint

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Off Script: Focusing on the Future

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content